Abstract: A recoverable instant thickening acid and its reusing method is usable for the recycling and reusing of a gas well carbonate reservoir acidizing fluid and production stimulation operation. The recoverable instant thickening acid includes the following components in weight percentage: 1.5-3 parts of a thickener, 0.5-3 parts of potassium chloride and 100 parts of a hydrochloric acid solution, wherein the thickener is a mixture composed of a mass ratio of 40%-70% of N-lauryl-N?-hydroxyethyl-N?-hydroxypropyl ethylenediamine propionate or its derivatives, 4%-12% of ethanol and 18%-56% of water. With the thickening acid for performing an acidizing treatment, the residual acid solution can be re-prepared as a thickening acid for an acidizing treatment without a chemical treatment, assisting the green and environmentally friendly production and sustainable development of gas fields.

Abstract: A recoverable instant thickening acid and its reusing method is usable for the recycling and reusing of a gas well carbonate reservoir acidizing fluid and production stimulation operation. The recoverable instant thickening acid includes the following components in weight percentage: 1.5-3 parts of a thickener, 0.5-3 parts of potassium chloride and 100 parts of a hydrochloric acid solution, wherein the thickener is a mixture composed of a mass ratio of 40%-70% of N-lauryl-N?-hydroxyethyl-N?-hydroxypropyl ethylenediamine propionate or its derivatives, 4%-12% of ethanol and 18%-56% of water. With the thickening acid for performing an acidizing treatment, the residual acid solution can be re-prepared as a thickening acid for an acidizing treatment without a chemical treatment, assisting the green and environmentally friendly production and sustainable development of gas fields.

Abstract: A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-?I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.

Abstract: A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-?I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.

Abstract: A synchronizable optomechanical oscillator (OMO) network including at least two dissimilar silicon nitride (Si3N4) optomechanical resonators that can be excited to evolve into self-sustaining optomechanical oscillators (OMOs) coupled only through an optical radiation field. The tunability of the optical coupling between the oscillators enables one to externally control the dynamics and switch between coupled and individual oscillation states.

Abstract: A synchronizable optomechanical oscillator (OMO) network including at least two dissimilar silicon nitride (Si3N4) optomechanical resonators that can be excited to evolve into self-sustaining optomechanical oscillators (OMOs) coupled only through an optical radiation field. The tunability of the optical coupling between the oscillators enables one to externally control the dynamics and switch between coupled and individual oscillation states.